HAP Trading’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-10,700
| Closed | -$9.81K | – | 730 |
|
|
2024
Q2 | $9.81K | Buy |
+10,700
| New | +$714K | ﹤0.01% | 577 |
|
|
2023
Q4 | – | Sell |
-11,100
| Closed | -$16.3K | – | 1042 |
|
|
2023
Q3 | $16.3K | Buy |
+11,100
| New | +$854K | ﹤0.01% | 704 |
|
|
2023
Q2 | – | Sell |
-19,200
| Closed | -$8K | – | 1204 |
|
|
2023
Q1 | $8K | Sell |
19,200
-172,500
| -90% | -$14.3M | ﹤0.01% | 919 |
|
|
2022
Q4 | $27K | Buy |
191,700
+74,900
| +64% | +$5.93M | ﹤0.01% | 873 |
|
|
2022
Q3 | $295K | Sell |
116,800
-800
| -0.7% | -$50.4K | 0.02% | 477 |
|
|
2022
Q2 | $320K | Sell |
117,600
-50,100
| -30% | -$3.1M | 0.02% | 556 |
|
|
2022
Q1 | $651K | Sell |
167,700
-99,500
| -37% | -$6.36M | 0.03% | 458 |
|
|
2021
Q4 | $185K | Buy |
267,200
+207,800
| +350% | +$14.3M | 0.01% | 1053 |
|
|
2021
Q3 | $230K | Sell |
59,400
-15,800
| -21% | -$1.11M | 0.01% | 978 |
|
|
2021
Q2 | $232K | Buy |
75,200
+16,100
| +27% | +$1.08M | 0.01% | 949 |
|
|
2021
Q1 | $353K | Sell |
59,100
-58,100
| -50% | -$3.75M | 0.02% | 594 |
|
|
2020
Q4 | $746K | Buy |
117,200
+9,600
| +9% | +$579K | 0.02% | 501 |
|
|
2020
Q3 | $538K | Sell |
107,600
-17,600
| -14% | -$1.22M | 0.03% | 394 |
|
|
2020
Q2 | $246K | Sell |
125,200
-11,000
| -8% | -$843K | 0.01% | 634 |
|
|
2020
Q1 | $381K | Sell |
136,200
-28,900
| -18% | -$2M | 0.03% | 390 |
|
|
2019
Q4 | $328K | Buy |
165,100
+20,000
| +14% | +$1.3M | 0.02% | 377 |
|
|
2019
Q3 | $648K | Buy |
145,100
+2,500
| +2% | +$163K | 0.05% | 271 |
|
|
2019
Q2 | $572K | Sell |
142,600
-6,600
| -4% | -$434K | 0.04% | 317 |
|
|
2019
Q1 | $887K | Buy |
149,200
+118,100
| +380% | +$7.85M | 0.08% | 202 |
|
|
2018
Q4 | $196K | Sell |
31,100
-7,100
| -19% | -$496K | 0.01% | 551 |
|
|
2018
Q3 | $111K | Sell |
38,200
-5,800
| -13% | -$438K | 0.01% | 533 |
|
|
2018
Q2 | $183K | Buy |
44,000
+17,900
| +69% | +$1.26M | 0.01% | 478 |
|
|
2018
Q1 | $138K | Sell |
26,100
-33,800
| -56% | -$2.69M | 0.01% | 506 |
|
|
2017
Q4 | $175K | Buy |
59,900
+20,200
| +51% | +$1.53M | 0.01% | 515 |
|
|
2017
Q3 | $58K | Sell |
39,700
-4,300
| -10% | -$329K | ﹤0.01% | 639 |
|
|
2017
Q2 | $181K | Sell |
44,000
-75,400
| -63% | -$5.02M | 0.01% | 527 |
|
|
2017
Q1 | $1.01M | Buy |
119,400
+38,000
| +47% | +$2.67M | 0.06% | 231 |
|
|
2016
Q4 | $623K | Buy |
81,400
+30,600
| +60% | +$2.27M | 0.03% | 317 |
|
|
2016
Q3 | $191K | Sell |
50,800
-101,900
| -67% | -$8.28M | 0.01% | 510 |
|
|
2016
Q2 | $287K | Buy |
152,700
+94,800
| +164% | +$8.41M | 0.02% | 388 |
|
|
2016
Q1 | $211K | Sell |
57,900
-147,400
| -72% | -$13.3M | 0.02% | 392 |
|
|
2015
Q4 | $540K | Buy |
205,300
+112,000
| +120% | +$11.7M | 0.03% | 365 |
|
|
2015
Q3 | $532K | Sell |
93,300
-101,100
| -52% | -$11.2M | 0.03% | 362 |
|
|
2015
Q2 | $295K | Buy |
194,400
+115,400
| +146% | +$12.6M | 0.02% | 412 |
|
|
2015
Q1 | $311K | Sell |
79,000
-33,000
| -29% | -$3.35M | 0.02% | 396 |
|
|
2014
Q4 | $112K | Buy |
112,000
+30,400
| +37% | +$3.14M | ﹤0.01% | 624 |
|
|
2014
Q3 | $41K | Sell |
81,600
-2,500
| -3% | -$245K | ﹤0.01% | 771 |
|
|
2014
Q2 | $67K | Buy |
84,100
+16,600
| +25% | +$1.29M | ﹤0.01% | 701 |
|
|
2014
Q1 | $201K | Buy |
+67,500
| New | +$5.29M | 0.01% | 612 |
|
Other funds holding GILD
HAP Trading's GILD Position: Q3 2025 in Review
HAP Trading sold out of Gilead Sciences (GILD) in Q3 2025, closing a stake of 24,620 shares — an estimated $2.73M sold.
HAP Trading first reported a position in GILD in Q1 2014 and held it in 23 quarters. The position peaked at $17.8M in Q4 2021. 2,027 funds tracked by Wall St. Rank hold GILD as of Q3 2025.
- HAP Trading reported no remaining Gilead Sciences position as of Q3 2025 after selling out during the quarter.
- HAP Trading sold 24,620 Gilead Sciences shares in Q3 2025, an estimated $2.73M.
- HAP Trading first reported a position in Gilead Sciences in Q1 2014 and held it in 23 quarters.
- HAP Trading's Gilead Sciences position peaked at $17.8M in Q4 2021.
- 2,027 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2025.
Based on HAP Trading's 13F filing for Q3 2025, filed 12 Nov 2025.